Financing Across Sectors for Sustainable Development - Guidance Note. Remme M, McGuire F, Guthrie T, et al. (2019)
 |
This guidance note builds on UNDP’s Strategic Plan 2018–2021 which recognizes UNDP as an integrator to support “greater collaboration across sectors and partners to deliver impacts at scale and to utilize limited resources efficiently.” The guidance note also build on UNDP’s HIV, Health and Development Strategy 2016–2021 which stresses the need for “innovative approaches that harness synergies across the goals […] particularly given the need to make the most efficient and effective use of available development resources."
|
Donor Government Funding for HIV in Low- and Middle-Income Countries in 2018. Kates J, Wexler A, Lief E and UNAIDS. (2019)
 |
This report provides the latest data on donor government resources available to address HIV in low- and middle-income countries, reporting on disbursements made in 2018. It is part of a collaborative tracking effort between UNAIDS and the Kaiser Family Foundation that began more than 15 years ago, just as new global initiatives were being launched to address the epidemic.
|
A Healthier Humanity: the WHO Investment Case for 2019-2023. WHO. (2018)
 |
This investment case describes how a stronger, more efficient and results oriented WHO can serve and guide governments and partners in their efforts to improve the health of their populations and to achieve Sustainable Development Goal 3. WHO will achieve results: The five years to 2023 will determine whether the world will achieve the health- related SDGs. Early investment in WHO will keep the world on track towards SDG3 and the other health-related targets.
Keywords: HIV, UHC, SDG, gender, human rights
|
Malaysia Health Expenditure Report 1997-2016. Malaysia National Health Accounts (MNHA) Section. (2018)
 |
This publication on the Malaysia National Health Accounts (MNHA) contains twenty years national health expenditure data from 1997 to 2016, estimated using standardised and internationally acceptable National Health Accounts (NHA) methodology. The reporting format follows closely the MNHA Framework and is kept almost similar to previous reporting format with the addition of a few editorial improvements for ease of reading and new sections.
|
Investing to End Epidemics: The Global Fund Strategy 2017-2022. The Global Fund. (2018)
 |
The Global Fund Strategy 2017-2022, Investing to End Epidemics, was developed under the leadership of the Board of the Global Fund, with contributions from numerous partners and stakeholders who share common goals in global health. Over a two-year period, in 2014 and 2015, the Board’s Strategy, Investment and Impact Committee led a broadly consultative process to collect the strongest ideas, perspective and guidance to formulate the Strategy.
|
2017 National Situational Assessment on HIV Financing in Indonesia, Malaysia, Thailand, and the Philippines. SHIFT. (2018)
 |
SHIFT has created country-specific snapshots of its 2017 National Situational Assessment report on HIV Financing in Indonesia, Malaysia, Thailand, and the Philippines. The National Situational Assessment Report assesses the availability and sufficiency of HIV financing resources, as well as how resources are equitably and efficiently allocated across these four countries. The country snapshot provides an executive summary of the 4 countries as well as an in-depth review for each country. By providing a current snapshot on HIV financing in Indonesia, Malaysia, Thailand, and the Philippines, the assessment outlines HIV expenditure against HIV epidemiology, identifies national HIV financing mechanisms, and describes national budget cycles and processes where available.
- National Situational Assessment on HIV Financing in Malaysia
- National Situational Assessment on HIV Financing in Thailand
- National Situational Assessment on HIV Financing in the Philippines |
HIV Prevention Research and Development Investments, 2017: Investing to End the Epidemic. AVAC. (2018)
 |
Flat and/or reduced funding for HIV/AIDS and other global health issues threatens to roll back progress worldwide. There is belated and widespread acknowledgment of a prevention crisis that can only be addressed by taking today’s tools to scale while researching new ones. Given this backdrop, the report is a powerful advocacy tool. This year’s report notes troubling trends in investment flows for biomedical HIV prevention at a moment of major promise in the research landscape. The report tracks the origins, trends and direction of global funding as well as the resulting effect(s) on the prevention research funding landscape.
|
2017 National Situational Assessment on HIV Financing in Indonesia, Malaysia, Thailand, and the Philippines. SHIFT. (2018)
|
SHIFT has created country-specific snapshots of its 2017 National Situational Assessment report on HIV Financing in Indonesia, Malaysia, Thailand, and the Philippines. The National Situational Assessment Report assesses the availability and sufficiency of HIV financing resources, as well as how resources are equitably and efficiently allocated across these four countries. The country snapshot provides an executive summary of the 4 countries as well as an in-depth review for each country. By providing a current snapshot on HIV financing in Indonesia, Malaysia, Thailand, and the Philippines, the assessment outlines HIV expenditure against HIV epidemiology, identifies national HIV financing mechanisms, and describes national budget cycles and processes where available.
- National Situational Assessment on HIV Financing in Malaysia
- National Situational Assessment on HIV Financing in Thailand
- National Situational Assessment on HIV Financing in the Philippines |
Donor Government Funding for HIV in Low- and Middle-Income Countries in 2016. Kates J, Wexler A, Lief E and UNAIDS. (2017)
 |
This report provides the latest data on donor government resources available to address HIV in low- and middle-income countries. It is part of a collaborative effort between UNAIDS and the Kaiser Family Foundation that began more than a decade ago, just as new global initiatives were being launched to address the epidemic. This current report provides data on donor government disbursements in 2016, the most recent year available.
|
Global Investment in HIV Cure Research and Development in 2016: Funding for a Cure Remains a Priority. AVAC. (2017)
 |
Antiretroviral treatment (ART) has radically changed the face of HIV infection, from a lethal disease into a manageable chronic condition. All 37 million people currently living with HIV are now eligible for ART based on the 2015 WHO Guidelines for ARVs for treatment and prevention - unfortunately, the latest data from December 2016 shows that only 18.2 million of these individuals are currently accessing ART. At the same time, daily antiretroviral regimens are costly and sometimes difficult for patients and most importantly not curative. HIV persists despite even the best treatment, and contributes to the development of non-AIDS morbidity.
|
Pages
